当前位置: X-MOL 学术Cardiovasc. Interv. Radiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiovascular Comorbidities Do Not Impact Prostate Artery Embolisation (PAE) Outcomes: Retrospective Analysis of the National UK-ROPE Registry
CardioVascular and Interventional Radiology ( IF 2.8 ) Pub Date : 2023-11-27 , DOI: 10.1007/s00270-023-03608-6
Ganesh Vigneswaran 1, 2 , Drew Maclean 1 , Neel Doshi 1, 2 , Mark Harris 3 , Timothy J C Bryant 1 , Nigel C Hacking 1 , Bhaskar Somani 3 , Sachin Modi 1
Affiliation  

Purpose

Prostate artery embolisation (PAE) is a key treatment for the management of symptomatic benign prostatic hyperplasia (BPH). Common cardiovascular risk factors might be associated with suboptimal outcomes and thus influence patient treatment selection. The aim of the study was to evaluate whether cardiovascular comorbidities affect PAE outcomes.

Methods

Retrospective subset analysis of the UK Registry of Prostate Artery Embolisation (UK-ROPE) database was performed with patients who had a full documented past medical histories including hypertension, diabetes, coronary artery disease (CAD), diabetes and smoking status as well as international prostate symptom score (IPSS) at baseline and at 12 months. Multiple regression was performed to assess for any significant predictors.

Results

Comorbidity data were available for 100/216 patients (mean age 65.8 ± 6.4 years), baseline IPSS 20.9 ± 7.0). Regression analysis revealed that the presence of hypertension (53.7% IPSS reduction vs. absence 51.4%, p = 0.94), diabetes (52.6% vs. absence 52.1%, p = 0.6), CAD (59.2% vs. absence 51.4%, p = 0.95), no comorbidities (49.8% vs. any comorbidity present 55.3%, p = 0.66), smoking status (non-smoker, 52.6%, current smoker, 61.5%, ex-smoker, 49.8%, p > 0.05), age (p = 0.52) and baseline Qmax (p = 0.41) did not significantly impact IPSS reduction at 12 months post-PAE. Baseline prostate volume significantly influenced IPSS reduction (≥ 80 cc prostates, 58.9% vs. < 80 cc prostates 43.2%, p < 0.05).

Conclusion

The presence of cardiovascular comorbidities/smoking history does not appear to significantly impact PAE symptom score outcomes at 12 months post procedure. Our findings suggest that if the prostatic artery can be accessed, then clinical success is comparable to those without cardiovascular comorbidities.

Graphical Abstract



中文翻译:


心血管合并症不会影响前列腺动脉栓塞 (PAE) 的结果:国家 UK-ROPE 登记的回顾性分析


 目的


前列腺动脉栓塞(PAE)是治疗症状性良性前列腺增生(BPH)的关键治疗方法。常见的心血管危险因素可能与次优结果相关,从而影响患者的治疗选择。该研究的目的是评估心血管合并症是否影响 PAE 结局。

 方法


对英国前列腺动脉栓塞登记 (UK-ROPE) 数据库进行了回顾性子集分析,对象是具有完整病史记录的患者,包括高血压、糖尿病、冠状动脉疾病 (CAD)、糖尿病和吸烟状况以及国际前列腺病史基线和 12 个月时的症状评分 (IPSS)。进行多元回归以评估任何显着的预测因素。

 结果


100/216 名患者(平均年龄 65.8 ± 6.4 岁)的合并症数据可用,基线 IPSS 20.9 ± 7.0)。回归分析显示,存在高血压(IPSS 降低 53.7% 对比不存在 51.4%, p = 0.94)、糖尿病(52.6% 对比不存在 52.1%, p = 0.6)、CAD(59.2% 对比不存在 51.4%, p = 0.95),无合并症(49.8% vs. 任何合并症 55.3%, p = 0.66),吸烟状况(不吸烟者,52.6%,当前吸烟者,61.5%,戒烟者,49.8%, p > 0.05),年龄 ( p = 0.52) 和基线 Qmax ( p = 0.41) 对 PAE 后 12 个月的 IPSS 减少没有显着影响。基线前列腺体积显着影响 IPSS 减少(≥ 80 cc 前列腺,58.9% vs. < 80 cc 前列腺 43.2%, p < 0.05)。

 结论


术后 12 个月时,心血管合并症/吸烟史似乎不会显着影响 PAE 症状评分结果。我们的研究结果表明,如果可以进入前列腺动脉,那么临床成功率与没有心血管合并症的患者相当。

 图形概要

更新日期:2023-11-28
down
wechat
bug